N
Google TrendJONAS BROTHERS (500+) — Jonas Brothers postpone Birmingham concert over weather concerns
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:jonas brothers500+steven kwan500+kings vs warriors200+steffi graf200+boxing200+ben simmons500+lisa500+bill maher500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Antengene Announces 2025" (26 stories)

Top Headline Story

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
Lead StoryYahoo Financeworld
1d ago

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPYU5BaExZRmdTdThmVXZPSkF6UmZHVEpVd2UyeGhyMVRmSXJKdUhTUWowbWExYjRwdTQwbktLZldpNFZqUlFHQ0FTb2g1WVFCRlN6ZGZIdDYySEx5SXljZXoydjYwZ0R1VzJtbzdkbkpTV0FaWXZMZUYtckNDUmhLQXpDV3JkUlNDZ1ZyeEVDWWRCT2pwOTNOVzUzUFFiQldqaWd0a3hIbHM?oc=5" target="_blank">Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+16m ago

jonas brothers

Jonas Brothers postpone Birmingham concert over weather concerns

Filter stories
500+16m ago

steven kwan

Guardians' Steven Kwan Could Shake Up Winter Outfield Market

Filter stories
200+16m ago

kings vs warriors

3 Storylines I'm Focused On in Warriors Preseason Game vs. Kings

Filter stories
200+16m ago

steffi graf

PICTURES: Steffi Graf & Daughter Jaz Feature In Andre Agassi’s ‘Photo Dump’ As Carlos Alcaraz & Karl-Anthony Towns Make Surprise Appearance

Filter stories

Search Results for "Antengene Announces 2025"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

25 stories displayed
Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
BioSpaceworld

Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability

<a href="https://news.google.com/rss/articles/CBMikwJBVV95cUxQemRnZ1J3UWFGUGhReUVFWVFuR0dzMTJQSUloNVF1cU5GM1hvYnRacnVqaWVWVzA5V3ZxMzhoTEdSa2MtbzQ3TUZDLWJhcTRMTVZveVhVY0VNVWdybU9zcE9kZVhDeHBJcWNNT2VkZ0MyMVZKSk1YdWNnYUp6Z2dyODk2dE95UmhnODJwUzQ3VG01UzRGc19FNGVKVjJ3WmZDSlpSUF9tcEQ1bEFuY2hTTWhhc01PdnZPWTRXcllsUm9RLVlQY1BJdnc2dmtacjNySkJwN0ZTbTU5SWpSamowYi1PalRNbDFVai1yQWgwTDl2T2w0Vzl2N2x5RWNrY3BGeFhiemljeXJTUkktOGQwOWJPRQ?oc=5" target="_blank">Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
Berkshire eagleworld

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

<a href="https://news.google.com/rss/articles/CBMipAJBVV95cUxNSVRwUXladDRFU09KMGhYS0c3MS0ydkJvS1plemFmQl95ZnBZLUpOejhrYm5RcW92dm44OS1YSjg4b1BlU3djMGRGR2NTU3hLLUlTOGdsYU5YNzVSdENyRnR6ZXU1OTNjekpLNTVTalVfWjFncHdKZ0FuVXNJSlpHTDN6ZnVlSGFnTDBCRXVzMm1QQjQ1R3RhQ0VsY1MzUEZob1o0UDF3WWNGc2Y5UVhQcHA1ZE0ydy1JVmFZU2pSaGJKQWV4OC1qcU1xemV3bFBGd2xGWHhVYTFXU1RPZl9ON1BKd1pWMFZoNGJuYkluWk1hWHE1UFhkYkFwbHpiQXpQUV8wa2E5R2oyLUtjQ2l1eTBpcWd3VkprcndWYk9yNjVSR0th?oc=5" target="_blank">Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022</a>  <font color="#6f6f6f">Berkshire eagle</font>

Read Full StoryMore like this
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
Morningstarworld

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

<a href="https://news.google.com/rss/articles/CBMilgJBVV95cUxNNUplamdDaFN3cUkwY09Bank1X3A3T3pmSXViWnNTYlR6Z1lVaVl2YVVQN3djSU54dmV3R1V3RGFTX0lmWGw1UkNkbGtNMU02enUwZ3VFQ2k5WnJfbWQtRDFtR19DMGN0aUZNU2g4M2g3T295cEJUWFlvOGRNcDBNT3RKUnV1amlVak16U0ExRlE0TlRaN3FkNXFnYWR1UHdlYXYzak9oUlpELWVyQkZYSjdXTUdkYXRXbHNUcTZNNFdjQ2M1bkNhMnpyRTNhQlM4N21wYXRfcGN5d3ZXZ1AwZ3ItV1RuVTEzZkRNcGxqNEdYZmFoa1NYY3lLR2l3LS11dFQ1RDNYZ2VMc2NtT1dPWVkzUmJTUQ?oc=5" target="_blank">Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D</a>  <font color="#6f6f6f">Morningstar</font>

Read Full StoryMore like this
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
Yahoo Financeworld

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQQi1OaE9DSDJqMFRsVHViQ1RoWHdvUFBhaXh1TEJoUTltYTdhb0lRa1VXd0pNYjdYeXUzM3dGOUNaeUVhV25DVEZ2anVHZkNaRmptOFc2YUNES251a0x1dEo1RXQzdVFOQmdBRkVxTjFidVpJbmJmQTk1SHdqaFhhTHdwTk1fTGlRLUlaMXE2S3E3SXd3YlJaNkIwT1E3VHRuYkktN3NlMS1NcmJl?oc=5" target="_blank">Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
Plataforma Mediaworld

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

<a href="https://news.google.com/rss/articles/CBMiowJBVV95cUxQdzU4VGxpOTQtNFlkUjBsZldhZUp4dnczb0MwMkgwaU44NExmNjV5XzJFcE5EV3AtYU5xNjRtV2hLeFpUeTl2TkRFTV9tTm9CV0tpbHFabjNMYTB2R1B3YkJvelZWVjBCUG9YUFcwLTRRLTVZLVFtRmV2UUhpTGNfMW1kaVc5UVRiaThEa1JPVEg5ZklYMlVDb2paYTBKZGdsY2hhNjNPcWE3S3E2WXl5dW9SZnVnQXExN25YckhybDRkLXhqbEtHSUg5ZWV0X2Y1QUIyLW85akc3VlV1d2FnTzhWQzd3cE9pelFmeUdvbHJHZE5XV2ZoZ1VMOTlDamFJYkVOX1k5OGVwaGlaaFNwTVhJUE8xaEJtamJ6X1o5M3lnRDA?oc=5" target="_blank">Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy</a>  <font color="#6f6f6f">Plataforma Media</font>

Read Full StoryMore like this
Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
PR Newswiregeneral

Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOTlVZd1RWUG1DRE53UUJ2dTZGUXdnZWFBYzFyMm9MeFBJUzBWRHJpYVhFV3FyZHM3NmdKc01zdHlmYzc3RTFlNVRXTnJMUDU0TkxObEQwYkhQZGxzY3hQOU52cGhINWduSUJHaFdobXlqNE5MRnRsWHhUd0VUdWU0eGRCTlM0Mi1HMDUyblE2UEczYUJDV3h5dXljekF2bWlSZ096ZXZkQzM5S2tpRUxOVTV0MjF2NFk0VTduWHdLM2tXVE5Cejc3R1dkM0ltX2pvdGc?oc=5" target="_blank">Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
Yahoo Financegeneral

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYlNqTXlCU183YU9MUGVQRDVwa0hMVlJmaW1NVk51eXdmYWtlZ1R2SHF6Wl9RdWhYSzdnSy1OYWhlaUZSZF9NbHBUUzdTRlFUNXpHeVZpSEFIajZVUGFJREtRcjJ0Sjg2UHZfSlYyNFNLSXNMXzVHTUNsMFAzR1lObUlEbnFVdXJCN2RyU01fcDRCMXgzcDVUS2t5NjJSV1R3eTg0OG5STTlSTmc?oc=5" target="_blank">Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
BioSpacegeneral

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

<a href="https://news.google.com/rss/articles/CBMimgJBVV95cUxNbkFsNE9zc29VWGNWZDJqRWY3ZU5VTmc4NkVzelJHTWRCRWx3ODg4VmlvRGlaMTlZQ2lsU2pkWXc2Qzd3QXJObDJHWUVCWDFqSlh1UDdtMnFkdnBNWS1aR2VlSk9ERWd4ZUxfR3cwSmRjX2FkM0tybUJOUVhPbVdoU01OUVhGSnV1ek1rR2g3ek10RDZEMWd1MmloajZkSXRobVJFYm10LUJyM3hIc3l3bzM0Ylc2VElrZG5ETmZOTTM1ek0xM2VuZy0wYlVFRnF0LXRMVHB4SVY2c2VKNkVQWlhjampXaFg5a3ZGY2FoSndxNmpUWEtjS0RuNmhlbDNHVTRFblZ4aFo4NDFYTTNlcmtJZnAyYnVpWlE?oc=5" target="_blank">Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors
BioPharma APACgeneral

Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPVk5DSjdXTGhMelpJZ09wejJVemhyRGh5U2ZzTFVOb0J4dGlCZjV6WlI1U2czS21RTjJsR1I3WFI1MzhUNjZYYzNMQ0JJeVpPR2UtQmpYSWl6Xzg3dlpVVnQ0S0pfaEp3Vy01eXpOZENfMXBia3Q1b0pqdzlJQWg0dERIN0haajZYSndKNFJRWWpTQ2UxX0dxTGNlQjdjUzZkaV9qenpLX2JtUWdXRk1acEVGMWZQWlc2SGdKLUp6dzJ0dS1xNnN0ZmE4UmFsSjhRTHJCcEMxaEg5U1VjNjBFRjlIQU5WSnc?oc=5" target="_blank">Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors</a>  <font color="#6f6f6f">BioPharma APAC</font>

Read Full StoryMore like this
Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality
PR Newswiregeneral

Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxQc0phYUpkTk40M1JUVnJ3ZVhVRVk5c0NLM3hYYnZmWEoyM3pJRVotbmw1cWRyQmpBMy1Pc2R2dnJtZ2dBOE1odGR3R0Y0aXhkRGpqV3hYUVI0QXdQTVh2YkM1dVF6MmUxRkM2Q0lMMVBxWUlqLWZfTGs5di1XVDR4aUEtdDZKTERLNnk3OE5PN25SNHNCMXpoR0x4Zm92cWUwVE0wN0dybkZqQUhXRkxOVXplSnQ3SU15Qzd4WkxPR0s1dno1OXdoVkdqbk1ycEFzZEtKTVl1Nm5TbmRJMl9TOXh3Vlcta1lNQ3luVWNBZXBvQ3RTSnhZcnFB?oc=5" target="_blank">Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
Yahoo Financetech

Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNT19MVDJKX1k5WnZXbWgtSEZKSkF4S1lmMHNQT0Zkc1Q2Z1RHeHEzeFltbk1CUlh2VEVMQVkzT2NFcjlNWUtPdV9rNGpJVUkyM0M0ZEoyQ2o2d1ltc1NpeS1uSzNMa1l5ZUxwSmtidGhyRkYxcklYWDc3S2NBUlhjblIyZEJMUWcyLXc1alltT0VSYlJ1SEI4eGl4eXRKMmdLZGRzbG1CU20tblY1VWVPc194UkotZw?oc=5" target="_blank">Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
BioSpacegeneral

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)

<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxPRExzQ2twOFRNODhoSlRQV0tmejhOR3FhUnlPaGhTNkNkSHZteFJaOUpJMGNrUWtiZ2V3Z050MThsMThXcFpyeVFnVk5aYXdaamFCNFRRbWtSUUozbnRULTNqRFpmaFNGTm1GTXRZZm1JdXZFVWRwYnVIbExVVE5Wczh3Ym9BMWcycTVfTW5fUklKYnVKRUVfSEhFaEdHYlVjODRTOWhsUFJ6WVdKazdOYUtFUTBiRTFJdHA5cmtWcmRrdV9TN1Y2TzlSUVBhaEVzdkRaLUx3dmtxZU1EYVYzUlY5Q0V2YWNnNk9SdldNbmlfNFRUQm9TeWNsbl9QaFVDcy1mTV9JbXo0UQ?oc=5" target="_blank">Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)
Yahoo Financescience

AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdmVpSGNDWVY2RFc1STdiVVhrNDdpNUNWS1JBdzA0dlVGZDdsQ0RyQWxtblg3dE1JbGJoZmVWeGxFVzExUWNBenEwdnYxRHRZNnRBLXBodTNvS3gtbkUwbGRXNm8xdXl0MEROOFlKV1FjNGdzOFkzNkU2cXFHcHd4NFZGS1owbkJJdk5wVlVuRE9ZZTZmMnBxZTByMnM5MlRLZHc2RF9uWGhUdw?oc=5" target="_blank">AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
Plataforma Mediaworld

Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

<a href="https://news.google.com/rss/articles/CBMimwJBVV95cUxOQVJWRFp5V09PZjVUMnpnMmVZUmNBUzBJUFEtM244Nl9WMXpQb3FzV0ZWeHJZLWQ2cGR0U2haUUFnYkU1UDdCOUxYWWRBZEZURHdfSTNLNEVDWDlZRlZsMXJNWVhaLTd4WWNzQ1NaZlV0dUlqb2ZGRXBTYlVpYVBzUEQwcmwta19QdDFOZlhTZWd1dTI5QXdNQ2JVVlAyRjJ6X3BiLUpYZ3ppM05nYk9zS0pBb0J4M3lKUTFEUUZRLXo0a2xmd1JqLVdCby1NU3hVWTNhVTVQQzU2bkVtMnJMdjRWUDhqS25HSWdHQmpOTVpPQl82dUJORHloanFjZlQtS1JweFB1UTY2a0Ewb0lYQ0FCRFZjN2p4X3Nj?oc=5" target="_blank">Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug</a>  <font color="#6f6f6f">Plataforma Media</font>

Read Full StoryMore like this
UD Info DB Series SSD Drives Achieve FIPS 140-3 Validation
The Delta Newsgeneral

UD Info DB Series SSD Drives Achieve FIPS 140-3 Validation

<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxQRDRBNFVtLWtUVlVGbDBIMWwybTl2YWE1QTV1dzlRclVucmpIdzBwdTZ1a05iLUVSR0hnZHhUc0dhS2dVcjBxb2lRU3BtM2pOUVptRThFYVVoSHNudWJPY3JqLTRfaHdOSGNtV3RXMFBqRWxoSWdnRFN3VmRBZjhza2puYkpQcGJmTEpDbmtCcG5BR3p3dlJWQnoxdUJjaWxfWEtoVkdrWjlGTEVKTnZieUlzbFZyeG50N21mTFNPaHQtSWxlSzlrWWkwUU44Zkp0MGhYY3Q0Z1Z0bFcwWHVGZEVhaE9pMlV2WmEzRDVSZ1dQY0swZm5R?oc=5" target="_blank">UD Info DB Series SSD Drives Achieve FIPS 140-3 Validation</a>  <font color="#6f6f6f">The Delta News</font>

Read Full StoryMore like this
China biotech outlicensing tops US$52 billion in first 2 months
South China Morning Posttech

China biotech outlicensing tops US$52 billion in first 2 months

<a href="https://news.google.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?oc=5" target="_blank">China biotech outlicensing tops US$52 billion in first 2 months</a>  <font color="#6f6f6f">South China Morning Post</font>

Read Full StoryMore like this
Qiming Venture Partners Newsletter – August 2025
启明创投general

Qiming Venture Partners Newsletter – August 2025

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE91V05MUW5MRGhOYjlwbVNVb1JST1l2a0I5RWNaMmxKb1JFUUpfcUZIMnBvb1ltcVBJNWg0NVpVTW9rTjRyM0V5bDdBZnhCX2N4MERkLW1meVY?oc=5" target="_blank">Qiming Venture Partners Newsletter – August 2025</a>  <font color="#6f6f6f">启明创投</font>

Read Full StoryMore like this
Cango Inc. Reports Third Quarter 2025 Unaudited Financial Results
Plataforma Mediaworld

Cango Inc. Reports Third Quarter 2025 Unaudited Financial Results

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQaDdMUE03ckpRZzN2MzZNRml3R1R2X3FqU0hHeHNRNTJWSFZMc1VydlpGYlNYMUJRZGtRRzV3a0lici1mYTJGSGg5OWVFd2xwbzRyYm41dWYtVFloRFhYNlBkR1ZtUy12Q1JtVDV2MGpTbFV3T2JlQWR3b2JXMFVWLS1KSHBpSWM1UjNpaUJfSkQxX1ltX0p3Q29aNEJzcFpXbFNWNFltc0pGWnhnNENkNw?oc=5" target="_blank">Cango Inc. Reports Third Quarter 2025 Unaudited Financial Results</a>  <font color="#6f6f6f">Plataforma Media</font>

Read Full StoryMore like this
PEPSICO® ANNOUNCES LANDMARK GLOBAL PARTNERSHIP WITH MERCEDES-AMG PETRONAS F1 TEAM FOR 2026
Plataforma Mediaworld

PEPSICO® ANNOUNCES LANDMARK GLOBAL PARTNERSHIP WITH MERCEDES-AMG PETRONAS F1 TEAM FOR 2026

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQVWhIcF9kTDNhNllwMU5oTG1SSEg5eGFnLTBNQ2JaT2ZQeHNGVzVpbTVBaFNsRGxhczFqNU9ueGhta2JOampNSU5LalpsMlhIdHBnWF9FT3IxS0xWV2txOHNKTHJqbWY5SmNWU2plR2NTcEhrQUNyZDFxdW05bmxnbGNfZUxKTWhta2xDZWhPRGg3ekttdUx0UlA0cEo5NTA4Mm0wR0hOUXhfZTdIVGswenlTM0dxMVRnUlROTVVnbGtKenFFRUVEUzBJeHZqX0xJMUE?oc=5" target="_blank">PEPSICO® ANNOUNCES LANDMARK GLOBAL PARTNERSHIP WITH MERCEDES-AMG PETRONAS F1 TEAM FOR 2026</a>  <font color="#6f6f6f">Plataforma Media</font>

Read Full StoryMore like this
Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country
팜뉴스world

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE9tOTN5RFRYeXFBelM4dXJNdnVieEYwczJHNTR5NVBLMVE2UjVZT1BTLVFYUjBuTTFISExOelJvOFdWVUZZQ2hzSTRmM3lCN2JVdTBRWlByUmV6c1RKV0RyOEU0dE1qSDlNeXRYag?oc=5" target="_blank">Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country</a>  <font color="#6f6f6f">팜뉴스</font>

Read Full StoryMore like this
Qiming Venture Partners Newsletter – July 2025
启明创投general

Qiming Venture Partners Newsletter – July 2025

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1rQXM3MU9EbzVMV2Y2bk4xWnRVNHRSazBvV1prckhXX2hFR2NITnotRVMyU2ZqdW4tcTdEd2dlUFJaQzNkQTV4VDRzdEtqVGhYTEd0R2w0aHg?oc=5" target="_blank">Qiming Venture Partners Newsletter – July 2025</a>  <font color="#6f6f6f">启明创投</font>

Read Full StoryMore like this
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
Lelezardworld

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPNkxCZjB5WWZNQWMxWVJlYnd4aXRBOENVdGExUWV3S0diUVVvem9nazI3UmtUNWRJa1hBcDFRU2tsZzhIT05hYjlHUnFWLVJmSUJveDIyckdLTV9YRFFWSDBia2VYb3ZBalVRTEtOQ0Z1WllMS0NXel85dlFDZFlVNlpQZWJvSTlydE9tSHdJQzVaUTlXSTZrUm1KSkNuZzVHQUNpTGY5TjVEQUZqYjNoZjlxczBENHRYclA3WkhteVVqQ0tfMmo4ZldCSGJqajRGemc?oc=5" target="_blank">Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031</a>  <font color="#6f6f6f">Lelezard</font>

Read Full StoryMore like this
Bybit & Block Scholes Report: ETH Holds Key Level as SOL Growth Stagnates
Plataforma Mediageneral

Bybit & Block Scholes Report: ETH Holds Key Level as SOL Growth Stagnates

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVzVubHFQY1ljM1JCSUJCcmY1SDE0WkE4Q1VyYl94VzdlRXlCTllIV3Zna1JhM0VBWGlQQXFobm1tV3p6cGlyYWtiUFNQX0I3QklYUk1UT2M5cXIxek11MVpyNzhmeGlNLVZMSW1zak0zMjRjaU1ZTXUxSkRRdjl0VTg4a3kycGg3eVRybUc1LWZ0dTA1ZDQwbUowYzFVUU5tUG9XbHFpVUVEZS1TTFRjNjFZWlc3NDU4?oc=5" target="_blank">Bybit & Block Scholes Report: ETH Holds Key Level as SOL Growth Stagnates</a>  <font color="#6f6f6f">Plataforma Media</font>

Read Full StoryMore like this
HLB, Antengene fail to gain U.S. FDA approval for liver cancer drug combo - CHOSUNBIZ
Chosunbiztech

HLB, Antengene fail to gain U.S. FDA approval for liver cancer drug combo - CHOSUNBIZ

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPazB6ZnBaSHpCcFplXzlBZXJwY3hRdnhvNmtXbXNRbnR0ZDdzYlNDNDdQcjRFY0hWSTZLRE1YQ1V3bTVmYjJxZUUtb01lakJrM2FQV051YUpCNU0xOWZUbWZvdmh1MmNxS0VjVDVuWVdhOFg3YTNkVjZFS19wMnZjStIBlAFBVV95cUxPeGlzWWxlcmhEaXJkZ0JFblZBTWo4amZYX1hEcVJwVHVzM2VoMkRWaFl6b2lUQVdDVklXTkd6MmtjUjdUVnhDOU1XZjFSb2NhUkJjR1hnT0xldFpuc01mdWZtNnhjaGcyZ2l1SmxUeFpid01jUmxWenJfNnZ2ZGdXcno3TDVJYTc4LXZxUEM5QVdfS1o0?oc=5" target="_blank">HLB, Antengene fail to gain U.S. FDA approval for liver cancer drug combo - CHOSUNBIZ</a>  <font color="#6f6f6f">Chosunbiz</font>

Read Full StoryMore like this
CBD Guangzhou 2025 Wraps Up with International Attendance Rising by 47.22%
Plataforma Mediageneral

CBD Guangzhou 2025 Wraps Up with International Attendance Rising by 47.22%

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOaFdGSUdiYTB6N01sS1E1N3NQMVhiMEs1U2tpd2w5SUY3ckdLWVh1M2pwbmkyMTNTd1dURDF2Tkx3SkNMT3lEZ3FaQkFLMXdhcl95Y1RXeG9WRXZ0UGpVWmJ3S1N6OEtPV3VqcVhudkRSZUprRGgtVjluV2xZb0hUcnluZnFwV3hKcXNTX3ROYmtva1VvUjM0ZmFJNEdVZ1hXdF90cDAyYVUyRG80QmNmVkxyOWJ5NGpYZmR1Yw?oc=5" target="_blank">CBD Guangzhou 2025 Wraps Up with International Attendance Rising by 47.22%</a>  <font color="#6f6f6f">Plataforma Media</font>

Read Full StoryMore like this
"Antengene Announces 2025" — Live Google News Trends & Headlines